Semaglutide (5mg)
Semaglutide is a GLP-1 receptor agonist with a long half-life of approximately 7 days, approved for chronic weight management and glycemic control. The long half-life allows for once-weekly subcutaneous dosing. This educational protocol outlines a gradual weekly titration from 0.25 mg up to a 2.4 mg maintenance dose over 16+ weeks.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full Semaglutide encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. It promotes weight loss via multiple mechanisms: reducing appetite and food intake through CNS effects, delaying gastric emptying, and improving glycemic control via glucose-dependent insulin secretion. The extended half-life of ~7 days is due to albumin binding and resistance to DPP-4 degradation. Clinical trials have shown significant weight loss (average 10–15% body weight reduction).
Quick Start
- Reconstitution: Add 2.0 mL bacteriostatic water → ~ 2.5 mg/mL concentration.
- Weekly dose range: 250–2400 mcg (0.25–2.4 mg) once weekly (gradual escalation protocol).
- Storage: Lyophilized: freezer at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 28 days.
Standard / Gradual Titration (2 mL = ~2.5 mg/mL)
Route: Subcutaneous | Frequency: Once weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 250 mcg (0.25 mg) | 10 Units (0.10 mL) |
| Weeks 5–8 | 500 mcg (0.5 mg) | 20 Units (0.20 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 40 Units (0.40 mL) |
| Weeks 13–16 | 1700 mcg (1.7 mg) | 68 Units (0.68 mL) |
| Weeks 17+ (Maintenance) | 2400 mcg (2.4 mg) | 96 Units (0.96 mL) |
Studies report administration once weekly subcutaneously. This gradual titration protocol improves tolerability and is consistent with FDA-approved dosing strategies. Administer on the same day each week. Note: We use 2.0 mL reconstitution (vs. 3.0 mL) to keep the maximum maintenance dose under 1.0 mL per injection.
Related compounds
Reconstitution Steps
- Withdraw 2.0 mL of bacteriostatic water with a sterile syringe.
- Inject slowly down the side of the vial to minimize foaming; do not shake.
- Gently swirl or roll the vial until the powder is fully dissolved.
- Label the vial with the reconstitution date and refrigerate at 2–8 °C, protecting from light.
- Use the reconstituted solution within 28 days.
Protocol Overview
- Goal: Support chronic weight management via GLP-1 receptor activation, leading to reduced appetite.
- Schedule: Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation.
- Storage: Lyophilized frozen; reconstituted refrigerated; use within 28 days.
Dosing Protocol
- Weeks 1–4: 250 mcg (0.25 mg) once weekly.
- Weeks 5–8: 500 mcg (0.5 mg) once weekly.
- Weeks 9–12: 1000 mcg (1.0 mg) once weekly.
- Weeks 13–16: 1700 mcg (1.7 mg) once weekly.
- Weeks 17+ (Maintenance): 2400 mcg (2.4 mg) once weekly as a target maintenance dose.
- Break between cycles: After completing the cycle, a 4–8 week washout period is recommended before repeating. Semaglutide has a long half-life (~7 days)—the body requires time for full clearance and restoration of natural GLP-1 regulation.
Washout & Cycle Restart
When can I restart?
After completing the cycle, a 4–8 week washout period is recommended before repeating. Semaglutide has a long half-life (~7 days)—the body requires time for full clearance and restoration of natural GLP-1 regulation.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized (powder): Store at −20 °C in a cool, dry place. For short-term storage, 2–8 °C refrigeration is acceptable.
- Reconstituted (solution): Refrigerate at 2–8 °C and do not freeze. Use within 28 days.
- Allow vials to reach room temperature before opening.
Important Notes
- Administer on the same day each week; if a dose is missed, take it as soon as possible within 5 days.
- GLP-1 receptor agonists can cause gastrointestinal side effects (nausea, vomiting); gradual escalation helps minimize this.
- The 5 mg vial offers flexible dosing options—plan for 1 vial per 8 weeks during the initial escalation.
Potential Benefits & Side Effects
Potential Benefits:
- Significant weight loss (average 10–15% body weight reduction in clinical trials at 2.4 mg weekly).
- Improved glycemic control through enhanced glucose-dependent insulin secretion.
- Reduced appetite and food intake via central GLP-1 receptor activation.
- Cardiovascular benefits demonstrated in outcome trials.
- Convenient once-weekly dosing improves adherence.
Potential Side Effects:
- Gastrointestinal effects (most common): nausea, vomiting, diarrhea, constipation—typically mild.
- Injection site reactions: redness, swelling, or irritation (generally mild).
- Risk of hypoglycemia (when combined with insulin or sulfonylureas).
- Rare but serious: pancreatitis, gallbladder disease, acute kidney injury.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Thyroid C-cell tumors (medullary thyroid carcinoma)
In rodents, semaglutide caused dose-dependent thyroid C-cell tumors (medullary carcinoma). Contraindicated in patients with personal/family history of MTC or MEN 2.
📄 FDA Boxed Warning — Ozempic® / Wegovy® LabelAcute pancreatitis
Reports of acute pancreatitis, including necrotizing. Discontinue if suspected. Increased risk with history of pancreatitis.
📄 FDA Label — Ozempic®Cholelithiasis & cholecystitis
Increased risk of gallstones due to rapid weight change. 1.5–3% incidence in clinical trials.
📄 STEP Trials — NEJM 2021References
- PMC – Weekly Semaglutide for Weight Management — Review of mechanism, efficacy, and safety
View Source - PubMed – Semaglutide for Weight Loss in Obesity — Clinical trial data
View Source - NCBI Bookshelf – Semaglutide (StatPearls) — Pharmacology, clinical uses, dosages
View Source - Mayo Clinic – Semaglutide (Subcutaneous Route) — Clinical guidance on administration and side effects
View Source - PMC – Semaglutide 2.4 mg: Clinical Evidence — Weekly maintenance dose and clinical outcomes
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Ozempic® / Wegovy® · Type 2 diabetes / Obesity (2017)
Ozempic® / Wegovy® · Type 2 diabetes / Obesity (2018)
Ozempic® · Type 2 diabetes (2018)
Ozempic® · Type 2 diabetes (2021)
Ozempic® / Wegovy® · Type 2 diabetes / Obesity (2019)
Ozempic® / Wegovy® · Type 2 diabetes / Obesity (2018)
Ozempic® / Wegovy® · Type 2 diabetes / Obesity (2019)
Approved worldwide (7+ countries)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →